Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
54.28%
Operating Margin
46.79%
Net Margin
40.68%
Efficiency Metrics
Revenue per Expense Ratio
1.86
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
96.03%
Income Tax Rate
5.86%
EPS
3.2900000000
Balance Sheet Analysis
Current Ratio
2.80
Cash Ratio
0.78
Working Capital
$1.45B
Debt to Equity
0.94
Debt to Assets
45.30%
Equity Ratio
48.40%
Cash Flow Analysis
Operating Cash Flow Ratio
61.64%
Free Cash Flow Ratio
54.66%
CapEx to Revenue
6.98%
Dividends Paid
$916.53M
Stock Buybacks
$977.67M
Total Shareholder Returns
$1.89B
Cash Position Change
208.72%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 1.71%
Detailed Growth Metrics
Core Performance
Revenue
17.73%
Net Income
18.23%
EPS
9.67%
Operating Income
-4.80%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
7.17%
Operating Cash Flow
6.96%
Free Cash Flow
19.39%
Balance Sheet Health
Assets
-0.69%
Debt
3.38%
Book Value per Share
-10.41%
Inventory
100.00%
Shareholder Returns
Dividends per Share
1.71%
Shares Outstanding
7.88%
Long Term Trends
3Y Revenue/Share
16.67%
5Y Revenue/Share
7.26%
3Y Dividend/Share
2.16%
5Y Dividend/Share
13.53%